NO20092725L - Quinazoliner for PDK1 inhibering - Google Patents
Quinazoliner for PDK1 inhiberingInfo
- Publication number
- NO20092725L NO20092725L NO20092725A NO20092725A NO20092725L NO 20092725 L NO20092725 L NO 20092725L NO 20092725 A NO20092725 A NO 20092725A NO 20092725 A NO20092725 A NO 20092725A NO 20092725 L NO20092725 L NO 20092725L
- Authority
- NO
- Norway
- Prior art keywords
- quinazolines
- pdk1
- compounds
- pdk1 inhibition
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87697206P | 2006-12-22 | 2006-12-22 | |
| US99917007P | 2007-10-15 | 2007-10-15 | |
| PCT/US2007/088392 WO2008079988A2 (en) | 2006-12-22 | 2007-12-20 | Quinazolines for pdk1 inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092725L true NO20092725L (no) | 2009-09-22 |
Family
ID=39563215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092725A NO20092725L (no) | 2006-12-22 | 2009-07-17 | Quinazoliner for PDK1 inhibering |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20100216767A1 (pt) |
| EP (1) | EP2125755A2 (pt) |
| JP (1) | JP2010514693A (pt) |
| KR (1) | KR20090092287A (pt) |
| CN (1) | CN101652352A (pt) |
| AR (1) | AR065231A1 (pt) |
| AU (1) | AU2007336893A1 (pt) |
| BR (1) | BRPI0720563A2 (pt) |
| CA (1) | CA2673003A1 (pt) |
| CL (1) | CL2007003774A1 (pt) |
| CO (1) | CO6361927A2 (pt) |
| CR (1) | CR10833A (pt) |
| EA (1) | EA200900819A1 (pt) |
| EC (1) | ECSP099445A (pt) |
| IL (1) | IL198774A0 (pt) |
| MA (1) | MA31001B1 (pt) |
| MX (1) | MX2009006627A (pt) |
| NO (1) | NO20092725L (pt) |
| PE (1) | PE20081630A1 (pt) |
| SM (1) | SMP200900055B (pt) |
| SV (1) | SV2009003307A (pt) |
| TN (1) | TN2009000255A1 (pt) |
| TW (1) | TW200829558A (pt) |
| WO (1) | WO2008079988A2 (pt) |
| ZA (1) | ZA200903233B (pt) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| JPWO2009131173A1 (ja) * | 2008-04-23 | 2011-08-18 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| US8603945B2 (en) | 2008-07-23 | 2013-12-10 | The Regents Of The University Of California | Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants |
| ES2432414T3 (es) * | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Compuestos químicos |
| KR20110120878A (ko) * | 2008-12-29 | 2011-11-04 | 포비어 파마수티칼스 | 치환된 퀴나졸린 화합물 |
| KR20110116160A (ko) | 2009-02-13 | 2011-10-25 | 포비어 파마수티칼스 | 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-ａ〕피리딘 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR081960A1 (es) | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| CN101921238B (zh) * | 2010-08-04 | 2012-04-04 | 苏州大学附属第一医院 | 取代苯并氮杂环类衍生物的制备及其药理用途 |
| US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
| EP2632263A1 (en) * | 2010-10-29 | 2013-09-04 | Merck Sharp & Dohme Corp. | Novel thiazole-carboxamide derivatives as pdk1 inhibitors |
| DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| EP2642856B1 (en) * | 2010-11-24 | 2017-07-19 | The Ohio State University Research Foundation | Integrin-linked kinase inhibitors |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| DE102011008352A1 (de) | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| KR101972619B1 (ko) | 2011-09-29 | 2019-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐 유도체 |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| DK2872491T3 (da) * | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| CA2907964A1 (en) | 2013-03-26 | 2014-10-02 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| EA030631B1 (ru) | 2013-07-31 | 2018-09-28 | Новартис Аг | 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом |
| JPWO2015056782A1 (ja) * | 2013-10-17 | 2017-03-09 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| AU2014337064B2 (en) | 2013-10-18 | 2019-03-14 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| CA3188733A1 (en) * | 2015-02-24 | 2016-09-01 | Theoria Science Inc. | Method for diagnosing, preventing and treating cancer brain metastasis, and drug delivery system for enabling passage through blood-brain barrier |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3325100A4 (en) | 2015-07-17 | 2019-02-20 | Memorial Sloan-Kettering Cancer Center | COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS |
| EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| US10344033B2 (en) | 2015-10-02 | 2019-07-09 | Sentinel Oncology Limited | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| BR112020005489A2 (pt) | 2017-09-22 | 2020-09-24 | Jubilant Epipad Llc, | composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as prmt5 inhibitors |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| KR20220044495A (ko) * | 2019-07-04 | 2022-04-08 | 치루 레고르 테라퓨틱스 인코포레이티드 | Hpk1 억제제 및 그의 용도 |
| CN114315798B (zh) * | 2020-09-29 | 2025-03-25 | 安思科(苏州)医药科技有限公司 | 喹唑啉类化合物及其药物组合物 |
| US20230399327A1 (en) * | 2020-10-28 | 2023-12-14 | Adlai Nortye Biopharma Co., Ltd. | High activity hpk1 kinase inhibitor |
| CN113999206B (zh) * | 2021-12-31 | 2022-04-12 | 北京鑫开元医药科技有限公司 | 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用 |
| CN114533733A (zh) * | 2021-12-31 | 2022-05-27 | 北京鑫开元医药科技有限公司 | 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法 |
| WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
| WO2023143135A1 (zh) * | 2022-01-28 | 2023-08-03 | 赛诺哈勃药业（成都）有限公司 | 一种喹唑啉衍生物及其用途 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| WO2023218241A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
| CN119968360A (zh) * | 2022-12-23 | 2025-05-09 | 赛诺哈勃药业（成都）有限公司 | 喹唑啉类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1878727A4 (en) * | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| WO2008020203A1 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
| TW200829566A (en) * | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
-
2007
- 2007-12-20 AU AU2007336893A patent/AU2007336893A1/en not_active Abandoned
- 2007-12-20 CN CN200780047581A patent/CN101652352A/zh active Pending
- 2007-12-20 MX MX2009006627A patent/MX2009006627A/es not_active Application Discontinuation
- 2007-12-20 EA EA200900819A patent/EA200900819A1/ru unknown
- 2007-12-20 KR KR1020097012780A patent/KR20090092287A/ko not_active Withdrawn
- 2007-12-20 BR BRPI0720563-5A patent/BRPI0720563A2/pt not_active IP Right Cessation
- 2007-12-20 CA CA002673003A patent/CA2673003A1/en not_active Abandoned
- 2007-12-20 JP JP2009543225A patent/JP2010514693A/ja not_active Withdrawn
- 2007-12-20 US US12/448,390 patent/US20100216767A1/en not_active Abandoned
- 2007-12-20 WO PCT/US2007/088392 patent/WO2008079988A2/en not_active Ceased
- 2007-12-20 EP EP07869660A patent/EP2125755A2/en not_active Withdrawn
- 2007-12-21 AR ARP070105879A patent/AR065231A1/es unknown
- 2007-12-21 CL CL200703774A patent/CL2007003774A1/es unknown
- 2007-12-21 TW TW096149570A patent/TW200829558A/zh unknown
-
2008
- 2008-01-02 PE PE2008000067A patent/PE20081630A1/es not_active Application Discontinuation
-
2009
- 2009-05-11 ZA ZA200903233A patent/ZA200903233B/xx unknown
- 2009-05-14 IL IL198774A patent/IL198774A0/en unknown
- 2009-05-28 CR CR10833A patent/CR10833A/es not_active Application Discontinuation
- 2009-06-17 MA MA32005A patent/MA31001B1/fr unknown
- 2009-06-17 CO CO09062868A patent/CO6361927A2/es not_active Application Discontinuation
- 2009-06-19 TN TNP2009000255A patent/TN2009000255A1/fr unknown
- 2009-06-19 SV SV2009003307A patent/SV2009003307A/es not_active Application Discontinuation
- 2009-06-19 EC EC2009009445A patent/ECSP099445A/es unknown
- 2009-06-30 SM SM200900055T patent/SMP200900055B/it unknown
- 2009-07-17 NO NO20092725A patent/NO20092725L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008079988A2 (en) | 2008-07-03 |
| IL198774A0 (en) | 2010-02-17 |
| CA2673003A1 (en) | 2008-07-03 |
| KR20090092287A (ko) | 2009-08-31 |
| MA31001B1 (fr) | 2009-12-01 |
| AU2007336893A1 (en) | 2008-07-03 |
| CO6361927A2 (es) | 2012-01-20 |
| SV2009003307A (es) | 2010-05-21 |
| BRPI0720563A2 (pt) | 2014-02-04 |
| AR065231A1 (es) | 2009-05-27 |
| SMP200900055B (it) | 2010-05-07 |
| TN2009000255A1 (en) | 2010-10-18 |
| ECSP099445A (es) | 2009-07-31 |
| CN101652352A (zh) | 2010-02-17 |
| WO2008079988A9 (en) | 2011-05-12 |
| TW200829558A (en) | 2008-07-16 |
| EA200900819A1 (ru) | 2010-02-26 |
| SMAP200900055A (it) | 2009-09-07 |
| WO2008079988A3 (en) | 2008-10-16 |
| ZA200903233B (en) | 2010-04-28 |
| EP2125755A2 (en) | 2009-12-02 |
| MX2009006627A (es) | 2009-08-12 |
| CL2007003774A1 (es) | 2008-04-18 |
| CR10833A (es) | 2009-07-03 |
| PE20081630A1 (es) | 2008-12-14 |
| US20100216767A1 (en) | 2010-08-26 |
| JP2010514693A (ja) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092725L (no) | Quinazoliner for PDK1 inhibering | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| NO20092657L (no) | Bicyclic heterocyclic compounds as FGFR inhibitors | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| MX2009011211A (es) | Indoles sustituidos en la posicion 7 inhibidores de mci-1. | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| CL2012003503A1 (es) | Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos. | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| CR20140082A (es) | Polimorfos de inhibidores de cinasas | |
| NO20082089L (no) | Fosfatidylinositol 3-kinaseinhibitorer og deres anvendelse | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| BR112013026834A2 (pt) | composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
| EA201300080A1 (ru) | Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами | |
| SV2009003212A (es) | Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct | |
| DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
| MY161461A (en) | Akt and p70 s6 kinase inhibitors | |
| BR112012029994A2 (pt) | composto heterocíclicos como inibidores de janus quinase | |
| HK1205506A1 (en) | Protein kinase inhibitors | |
| MX2009012079A (es) | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |